Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: A randomized, open-label, multi-center study

Travel Medicine and Infectious Disease

Volumn 12, Issue 5, 2014, Pages 485-493

  Alberer, Martin ^a   Burchard, Gerd ^b   Jelinek, Tomas ^c   Reisinger, Emil ^d   Beran, Jiri ^e   Meyer, Seetha ^f   Forleo Neto, Eduardo ^f   Gniel, Dieter ^f   Dagnew, Alemnew F ^f   Kumar Arora, Ashwani ^f,g  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Berlin Center for Travel and Tropical Medicine   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e Vaccination and Travel Medicine Centre   (Czech Republic)

^f Novartis Vaccines and Diagnostics Inc ^*  (United States)

^g NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Co administration; Japanese encephalitis; Meningococcal disease; Rabies; Vaccine

Indexed keywords

INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; MENINGOCOCCUS VACCINE; RABIES VACCINE; ANTIMALARIAL AGENT; MENACWY; VACCINE;

ADJUVANT THERAPY; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHICK EMBRYO; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EMBRYO CULTURE; EMPORIATRICS; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEAD AND NECK INJURY; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INTENTION TO TREAT ANALYSIS; INTERVERTEBRAL DISK HERNIA; JAPANESE ENCEPHALITIS; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RABIES; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SERUM BACTERICIDAL ANTIBODY ASSAY; SINGLE DRUG DOSE; VACCINATION; VACCINATION REACTION; CLINICAL TRIAL; COMMUNICABLE DISEASES; CROSS-SECTIONAL STUDY; INFECTION CONTROL; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TRAVEL; YOUNG ADULT;

ADULT; ANTIMALARIALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; TRAVEL; TRAVEL MEDICINE; VACCINATION; VACCINES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84908158054     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2014.04.011     Document Type: Article

References (43)

1. Meningococcal vaccines: WHO position paper, November 2011 Wkly Epidemiol Rec 86 47 2011 521 539
2. L.K. Tan, G.M. Carlone, and R. Borrow Advances in the development of vaccines against Neisseria meningitidis N Engl J Med 362 16 2010 1511 1520
3. D. Pace, and A.J. Pollard Meningococcal disease: clinical presentation and sequelae Vaccine 30 Suppl. 2 2012 B3 B9
4. L.H. Harrison, C.L. Trotter, and M.E. Ramsay Global epidemiology of meningococcal disease Vaccine 27 Suppl. 2 2009 B51 B63
5. A.C. Cohn, J.R. MacNeil, T.A. Clark, I.R. Ortega-Sanchez, E.Z. Briere, and H.C. Meissner Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 62 RR-2 2013 1 28
6. ®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y Expert Rev Vaccines 10 1 2011 21 33
7. N.E. Rosenstein, B.A. Perkins, D.S. Stephens, T. Popovic, and J.M. Hughes Meningococcal disease N Engl J Med 344 18 2001 1378 1388
8. P.M. Dull, and E.D. McIntosh Meningococcal vaccine development-from glycoconjugates against MenACWY to proteins against MenB-potential for broad protection against meningococcal disease Vaccine 30 Suppl. 2 2012 B18 B25
9. ® among healthy adolescents Hum Vaccin 6 11 2010 881 887
10. L.A. Jackson, R. Baxter, K. Reisinger, A. Karsten, J. Shah, and L. Bedell Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents Clin Infect Dis 49 1 2009 e1 e10
11. N.P. Klein, K.S. Reisinger, W. Johnston, T. Odrlijn, C.J. Gill, and L. Bedell Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants Pediatr Infect Dis J 31 1 2012 64 71
12. K.P. Perrett, M.D. Snape, K.J. Ford, T.M. John, L.M. Yu, and J.M. Langley Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants Pediatr Infect Dis J 28 3 2009 186 193
13. M.D. Snape, K.P. Perrett, K.J. Ford, D. Pace, L.M. Yu, and J.M. Langley Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial JAMA 299 2 2008 173 184
14. R. Borrow Meningococcal disease and prevention at the Hajj Travel Med Infect Dis 7 4 2009 219 225
15. Ministry of Hajj. Umrah Visas. www.hajinformation.com/main/t1505.htm [accessed 11.02.14].
16. Cohn A, MacNeil JR. Meningococcal disease. In: centers for disease control and prevention. Yellow book. Chapter 3. http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/meningococcal-disease [accessed 11.02.14].
17. A. Wilder-Smith Meningococcal vaccines: a neglected topic in travel medicine? Expert Rev Vaccines 8 2009 1343 1350
18. G.L. Campbell, S.L. Hills, M. Fischer, J.A. Jacobsen, C.H. Hoke, and J.M. Hombach Estimated global incidence of Japanese encephalitis: a systematic review Bull World Health Organ 89 10 2011 766 774 774A-E
19. ® updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis Expert Rev Vaccines 12 8 2013 859 869
20. E. Tauber, H. Kollaritsch, M. Korinek, P. Rendi-Wagner, B. Jilma, and C. Firbas Safety and immunogenicity of a vero-cell-derived inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial Lancet 370 2007 1847 1853
21. M. Fischer, N. Lindsey, J.E. Staples, and S. Hills Centers for disease C, prevention. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 59 RR-1 2010 1 27
22. Hills SL, Weber IB, Fischer M. Japanese encephalitis. In: Centers for disease control and prevention. Yellow book. Chapter 3. http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/japanese-encephalitis [accessed 11.02.14].
23. D.L. Knobel, S. Cleaveland, P.G. Coleman, E.M. Fèvre, M.I. Meltzer, and M.E.G. Miranda Re-evaluating the burden of rabies in Africa and Asia Bull World Health Organ 83 2005 360 368
24. P. Gautret, and P. Parola Rabies vaccination for international travelers Vaccine 30 2 2012 126 133
25. WHO. Rabies vaccines. WHO Position Paper. WER 2010; 85:309-20.
26. WHO Expert consultation on rabies Second Report. WHO TRS 982 2013 WHO
27. Cl Malerczyk, L. DeTora, and D. Gniel Imported human rabies cases in europe, the United States, and Japan, 1990 to 2010 J Travel Med 18 2011 402 407
28. Rupprecht CE, Shlim DR. Rabies. In: Centers for disease control and prevention. Yellow book. Chapter 3. http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/rabies [accessed 11.02.14].
29. A.T. Kroger, C.V. Sumaya, L.K. Pickering, and W.L. Atkinson General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 60 2 2011 1 64
30. D.N. Taylor, C. Wasi, and K. Bernard Chloroquine prophylaxis associated with a poor antibody response to human diploid cell Rabies vaccine Lancet 1 8391 1984 1405
31. M. Pappaioanou, D.B. Fishbein, D.W. Dreesen, I.K. Schwatz, G.H. Campbell, and J.W. Sumner Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine N Engl J Med 314 5 1986 280 284
32. Menveo. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001095/WC500090147.pdf [accessed 13.09.13].
33. IXIARO. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000963/WC500037287.pdf [accessed 13.09.13].
34. Rabipur. Summary of product characteristics. http://www.eda.mohp.gov.eg/Download/Docs/Files/36-SPC.pdf [accessed 13.09.13].
35. S. Gizurarson Clinically relevant vaccine-vaccine interactions: a guide for practitioners BioDrugs 9 6 1998 443 453
36. J.R. Nascimento Silva, L.A. Camacho, M.M. Siqueira, S. Freire Mde, Y.P. Castro, and L. Maia Mde Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella Vaccine 29 37 2011 6327 6334
37. R. Vodopija, M. Lafont, Z. Baklaic, M. Ljubicic, M. Svjetlicic, and I. Vodopija Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine Vaccine 15 1997 571 574
38. D.J. Briggs, D.W. Dreesen, U. Nicolay, J.E. Chin, R. Davis, and C. Gordon Purified chick embryo cell culture rabies vaccine: interchangeability with human diploid cell culture rabies vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons Vaccine 19 2001 1055 1060
39. D.W. Dreesen A global review of rabies vaccines for human use Vaccine 1997 S2 S6
40. Valneva Austria GmbH. Comparison of three Commercial Batches of the Japanese encephalitis vaccine IC51. Double blind, randomized, controlled phase 3 study. ClinicalTrials.gov Identifier NCT00595465. Results published online at: http://clinicaltrials.gov/ct2/show/results/NCT00595465?term=IC51&rank=12§=X6015#outcome1 [accessed 24.10.13].
41. A. Kaltenboeck, K. Dubischar-Kastner, G. Eder, W. Jilg, C. Klade, and H. Kollaritsch Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study Vaccine 27 33 2009 4483 4489
42. K. Pengsaa, K. Limkittikul, A. Sabchareon, C. Ariyasriwatana, P. Chanthavanich, and P. Attanath A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine Pediatr Infect Dis J 28 4 2009 335 337
43. N.P. Klein, J. Shepard, L. Bedell, T. Odrljin, and P. Dull Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers Vaccine 30 26 2012 3929 3936